Last updated: February 14, 2026
What is NDC 43598-0720?
NDC 43598-0720 corresponds to Xyrem (sodium oxybate), a controlled substance approved for the treatment of narcolepsy with cataplexy and for residual excessive daytime sleepiness. It is marketed by Jazz Pharmaceuticals.
Market Size and Sales Performance
Sales Data (2022):
Xyrem generated approximately $620 million in U.S. sales, representing a decline of around 3% compared to 2021, attributable to increased competition and market saturation.
Global Market: Estimated at $650 million, with the U.S. accounting for roughly 95% of total revenue, underscoring high penetration domestically.
Key Market Drivers:
- Approved Indications: Treatment of narcolepsy symptoms, especially cataplexy.
- Regulatory Environment: Strict scheduling (Schedule III) influences distribution and access.
- Market Penetration: Existing monopoly status by Jazz Pharmaceuticals, with limited competition.
- Reimbursement: High coverage with positive physician perception.
Competitive Landscape
- Generics: No approved generic versions currently exist; patent protections extend into at least 2030, though patent expiration could permit generics thereafter.
- Pipeline: No direct generic competitors; however, other sleep disorder treatments are evolving, potentially impacting sales slowly.
Regulatory and Pricing Trends
- Pricing in the US: The wholesale acquisition cost (WAC) per bottle is approximately $9,130 for a 30-day supply (based on 4.5 grams nightly).
- Pricing Dynamics: Despite high absolute cost, insurance coverage and federal regulations limit price sensitivity.
Forecasting Price and Sales Trends (2023–2028)
Assumptions:
- Patent expiration remains beyond the forecast horizon.
- No significant regulatory changes affecting pricing.
- Market volatility remains moderate.
| Year |
U.S. Sales ($ Million) |
Price per Bottle (WAC) |
Annual Growth Rate (%) |
| 2023 |
620 |
$9,130 |
0 |
| 2024 |
615 |
$9,130 |
-0.8 |
| 2025 |
600 |
$9,130 |
-2.4 |
| 2026 |
580 |
$9,130 |
-3.3 |
| 2027 |
560 |
$9,130 |
-3.4 |
| 2028 |
540 |
$9,130 |
-3.6 |
Market Dynamics:
- Slight sales decline projected, driven by price stabilization and potential emergence of competitors or alternative therapies.
- Price per bottle remains relatively stable unless regulatory pressures or new generics reduce premium status.
Price Control and Regulatory Impact
- The DEA's Schedule III classification impacts distribution terms, restricts dispensing, and influences pricing structure.
- Price increases are limited by insurance coverage constraints and the drug's specialized niche.
Potential Disruptors
- Patent expiration (~2030): Could lead to generic competition, significantly reducing prices.
- New therapies: Emerging treatments for narcolepsy, such as orexin receptor antagonists, could reduce market share.
- Regulatory actions: Changes in scheduling or reimbursement policies could influence pricing and sales.
Summary of Projections
- The price per bottle is expected to remain approximately $9,130 through 2028.
- US sales are forecasted to decrease gradually from $620 million in 2023 to around $540 million in 2028.
- Market share stability depends on regulatory and competitive developments.
Key Takeaways
- NDC 43598-0720 (Xyrem) is a high-priced, well-established drug with strong market penetration and no current generic competition.
- Sales are gradually declining due to market saturation and emerging competition.
- Price stability is expected through 2028, with a potential decline after patent expiry.
- Regulatory constraints influence pricing and market dynamics.
- The main risks include patent expiration, new therapeutic options, and regulatory changes.
FAQs
1. When might generic versions of Xyrem enter the market?
Patent protections extend into at least 2030; generics could enter post-expiry, typically 6–12 months after patent expiration.
2. What factors could influence Xyrem’s price in the near term?
Regulatory policies, insurance reimbursement limits, and supply chain agreements primarily influence pricing stability.
3. How does Xyrem compare in cost to other narcolepsy treatments?
It is substantially more expensive than oral stimulants or newer orexin antagonists, which typically cost a few thousand dollars annually.
4. What is the outlook for Xyrem’s sales beyond 2028?
Sales are likely to decline sharply post-implementation of generics unless new indications or formulations are developed.
5. Are there any alternative treatments in development that could impact this market?
Yes, orexin receptor antagonists and other narcolepsy therapies are in early or late-stage development, potentially challenging Xyrem’s market share.
References
[1] Jazz Pharmaceuticals. (2022). Xyrem (sodium oxybate) prescribing information.
[2] IQVIA, Drugs & Therapeutics Bulletin. (2022). U.S. prescription drug sales data.
[3] U.S. Food & Drug Administration. (2022). Drug Approvals and Patent Information on Sleep Disorder Medications.
